HCPLive Podcasts Podcast Por HCPLive.com arte de portada

HCPLive Podcasts

HCPLive Podcasts

De: HCPLive.com
Escúchala gratis

Acerca de esta escucha

 Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.



 Ciencia Ciencias Biológicas Enfermedades Físicas Hygiene & Healthy Living Política y Gobierno
Episodios
  • HCPLive 5 Stories in Under 5: Week of 06/22

    HCPLive 5 Stories in Under 5: Week of 06/22
    Jun 30 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for June 16-22, 2025:
    Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial
    Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment.

    FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis
    The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN.

    Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension
    Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population.

    Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial
    COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial.

    Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year
    Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.
    Más Menos
    5 m
  • Medical Ethics Unpacked: Shifting Vaccine Regulation and Policy, with Jason Schwartz, PhD

    Medical Ethics Unpacked: Shifting Vaccine Regulation and Policy, with Jason Schwartz, PhD
    Jun 18 2025
    In this episode of Medical Ethics Unpacked, hosts Dominic Sisti and Steve Levine welcome Jason Schwartz, PhD, associate professor at the Yale School of Public Health, for a discussion on vaccine ethics, public health infrastructure, and the challenges of maintaining trust in immunization programs.

    Together, they explore how the COVID-19 pandemic reshaped public attitudes toward vaccines, while also underscoring long-standing tensions between individual autonomy and collective responsibility. Schwartz, whose work focuses on vaccine policy and history, offers perspective on the systems and institutions, such as the CDC's Advisory Committee on Immunization Practices (ACIP), helping to translate scientific evidence into public health recommendations.

    This episode comes at a time when ACIP is once again in the headlines as HHS Secretary Robert F. Kennedy Jr. recently replaced all 17 members with a new slate of individuals, citing concerns about groupthink and conflicts of interest. The move has generated widespread commentary about the role and value of such expert advisory bodies in shaping public health decisions, especially in the face of growing skepticism and political scrutiny.

    Ethical questions about equity, communication, and responsibility are threaded throughout the discussion. The hosts and Schwartz reflect on what it means to make fair vaccine recommendations in the context of incomplete data, and how institutions can maintain public trust amid scientific uncertainty. They also discuss how the infrastructure behind public health decisions—committees, advisory boards, and interagency coordination—can either strengthen or undermine confidence depending on how they function and how well they are understood.

    Chapters
    00:00 – Introduction and Vaccine Policy in Crisis
    03:00 – The Long History and New Politics of Vaccine Skepticism
    09:30 – Erosion of Public Health Infrastructure and Expert Advisory Systems
    14:50 – Why Vaccines Became a Political Flashpoint
    19:10 – Clinician Ethics and the Vaccine-Hesitant Patient
    32:00 – Data, Misinformation, and the Future of Vaccine Trust


    References:

    Stone W. RFK Jr. names new slate of vaccine advisers after purging CDC panel. NPR. Published June 11, 2025. Accessed June 17, 2025. https://www.npr.org/sections/shots-health-news/2025/06/11/nx-s1-5430870/cdc-vaccine-experts-rfk-jr

    Asturias EJ, Brewer NT, Brooks O, et al. Advisory Committee on Immunization Practices at a Crossroads. JAMA. Published online June 16, 2025. doi:10.1001/jama.2025.10776
    Más Menos
    46 m
  • HCPLive 5 Stories in Under 5: Week of 06/08

    HCPLive 5 Stories in Under 5: Week of 06/08
    Jun 14 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for June 2-8, 2025.

    FDA Approves Clesrovimab RSV Immunization for Newborns and Infants
    The FDA has approved clesrovimab (Enflonsia) for the prevention of RSV lower respiratory tract disease in infants, based on results from two late-stage clinical trials evaluating its safety and efficacy.

    FDA Approves Glecaprevir/Pibrentasvir (Mavyret) Label Expansion for Acute HCV
    The FDA has expanded the indication for glecaprevir/pibrentasvir to include treatment of acute hepatitis C virus infection in adults and children aged three years and older, regardless of cirrhosis status.

    FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
    Prednisolone acetate ophthalmic suspension 1% has received FDA approval as a topical steroid treatment for steroid-responsive ocular inflammation, with product launch expected later in 2025.

    FDA Grants Fast Track Designation to Mavorixafor for Chronic Neutropenia
    The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, supporting its ongoing phase 3 evaluation following earlier approval for WHIM syndrome.

    Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial
    Phase 3 data show iptacopan (Fabhalta) is effective and well-tolerated in adults with PNH who transitioned from anti-C5 therapy, achieving key hematologic outcomes and symptomatic improvement.
    Más Menos
    5 m
Todavía no hay opiniones